FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549
-------------	------	-------

Observation have if the desired	STA
Check this box if no longer subject	017
to Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

## ATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response	: 0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Singhal Priya				2. Issuer Name and Ticker or Trading Symbol BIOGEN INC. [ BIIB ]									k all app Direc	licable) tor	ng Pe	rson(s) to Is	vner			
(Last) 225 BIN	,	irst) (I	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 04/02/2024								X	Officer (give title below)  Head of De			Other (specify below)  velopment			
,						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)														X	Form	filed by On	e Rep	orting Perso	on	
CAMBR	IDGE M	IA 0	2142											Form filed by More than One Reporting Person						
(City)	(5	State) (2	Zip)		Rul	Rule 10b5-1(c) Transaction Indication														
							X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Table	I - No	on-Deriva	tive S	Secui	rities	Acc	quired	l, Dis	posed of	, or E	Benefic	ially	/ Own	ed				
1. Title of Security (Instr. 3)  2. Transactic Date (Month/Day/			Execution Date		,			Acquired (A) of (D) (Instr. 3, 4 a		and Securit Benefic Owned		ies cially Following	Forr (D)	m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership					
									Code	v	Amount	(A) or (D) Price			Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock 04/02				04/02/20	2024			S		93	D \$213.0		.09	9 4,886.4761(1)			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security		se (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	ition Date,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerci Expiration Da (Month/Day/Y		ate	7. Titl Amou Secur Under Derive Secur 3 and	int of rities rlying ative rity (Instr.	De Se	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y Dii or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amount or Number of Shares							

## **Explanation of Responses:**

1. 1. Includes 93.3846 shares acquired under the Biogen Inc. employee stock purchase plan on 3/28/2024.

/s/ Samuel Ntonme, attorneyin-fact for Priya Singhal

04/03/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.